Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement
Mandate

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

July 19, 2024 M&A

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.

Vinge has advised Embracer Group AB (publ) (“Embracer”) in connection with the entry into of a EUR 600 million financing agreement with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank. Embracer is a global group of entrepreneurial businesses in the gaming and entertainment industry.

The new facility of EUR 600 million is used to refinance Embracer’s existing revolving credit facilities of SEK 4.8 billion. The terms and conditions for the new facility have been improved, including a notably lower credit margin for utilised debt, which will reduce interest expenses through both improved terms and a reduced financial leverage.

Vinge’s team consisted of Albert Wållgren, Felix Möller, Ida Redander and Josef Groow.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025